The synergistic effects of paclitaxel and gemcitabine on prostate cancer cell line PC-3.
- Author:
Ming SUN
1
;
Yuru YANG
;
Hong LI
;
Yirong CHEN
;
Zhiping WANG
;
Yiping LU
;
Qiang WEI
;
Zhongjin YUE
Author Information
- Publication Type:Journal Article
- MeSH: Antimetabolites, Antineoplastic; pharmacology; Antineoplastic Agents, Phytogenic; pharmacology; Apoptosis; drug effects; Cell Line, Tumor; Deoxycytidine; analogs & derivatives; pharmacology; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Flow Cytometry; Humans; Male; Paclitaxel; pharmacology; Prostatic Neoplasms; pathology
- From: National Journal of Andrology 2004;10(9):658-666
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the synergistic effects of paclitaxel and gemcitabine on prostate cancer cell line PC-3 in vitro.
METHODSCell morphology, MTU, flow cytometer and immunocytochemical method were used to observe the effects of 10(-6), 10(-7), 10(-8) mol/L paclitaxel and 10(-7), 10(-8), 10(-9) mol/L gemcitabine on prostate cancer cell line PC-3 by single or synergistic administration for 48 hours in vitro.
RESULTSGemcitabine above 10(-8) mol/L enhanced the growth suppression [suppression ratio > or = (50.8 +/- 4.2)%, P < 0.05] and apoptosis [apoptosis ratio > or = (22.9 +/- 2.3)%, P < 0.05] and down-regulation of the expression of cyclin D1 [expression ratio < or = (9.6 +/- 1.6)%, P < 0.01] induced by paclitaxel above 10(-7) mol/L in PC-3 cells. Gemcitabine changed the ratio of G2/M cell arrest induced by paclitaxel from (70.3 +/- 9.7)% to (38.2 +/- 4.2)%, and reversed the G2/M arrest partially (P < 0.01).
CONCLUSIONPaclitaxel and gemcitabine can enhance the growth suppression and apoptosis induced by paclitaxel in a synergistic way. They show great potential in the treatment of androgen-independent carcinoma of the prostate.